pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,782 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT812Endpoints613BioPharma Dive235onclive165Fierce Biotech81BioSpace79raps32globenewswire health26
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
    Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
    STAT · 1mo ago↗ source
  • STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading data
    Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.
    STAT · 1mo ago↗ source
  • Bristol Myers turns focus to AI costs after broad rollout to workers
    PALO ALTO, CA — After giving artificial intelligence tools to thousands of employees, Bristol Myers Squibb is now working to get a handle on the costs of the technology and where it’s actually crea…
    Endpoints
← prev
page 41 of 72
next →
fda press21
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 1mo ago
↗ source
  • Axsome pushes back generic entry for narcolepsy drug until 2040
    Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040. The company announced on Wednesday that it has reached a settlement with the last applica…
    Endpoints · 1mo ago↗ source
  • FDA guides pharma on explaining unapproved drugs to payors
    Biopharma companies preparing to launch the next practice-changing blockbusters want payors to know what's coming before they ultimately land an FDA approval. The trick is to do that without stretc…
    Endpoints · 1mo ago↗ source
  • What it will take for more employer GLP-1 coverage
    Last week, Eli Lilly proclaimed that its weight loss shot and pill are now “covered for millions of Americans,” now that all three major pharmacy benefit managers have put the ...
    Endpoints · 1mo ago↗ source
  • Regeneron doubles down on CytomX after other pharmas walked away
    After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator. Regeneron is doubling down on its partnership with the Bay Area bi…
    Endpoints · 1mo ago↗ source
  • Mineralys makes money moves before looming hypertension approval
    Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator,…
    Endpoints · 1mo ago↗ source
  • STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
    In this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.
    STAT · 1mo ago↗ source
  • STAT+: Legend Biotech emerged as a rare market winner
    New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
    Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found
    STAT · 1mo ago↗ source
  • Is the military fueling eating disorders?
    A brief hantavirus update, some good news about death, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
    Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...
    Endpoints · 1mo ago↗ source
  • Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
    A survey finds that ultra-processed foods are a cross-partisan concern. And yet policy has been slow to follow.
    STAT · 1mo ago↗ source
  • Opinion: The medical-billing AI arms race between providers and insurance
    “The financial side effects of care have become clinical ones,” writes Darshak Sanghavi.
    STAT · 1mo ago↗ source
  • Opinion: The Amish way of health care
    “Public health is going to have to talk about the Amish more and more”: Listen to STAT’s "First Opinion Podcast" on the Amish and health care.
    STAT · 1mo ago↗ source
  • Opinion: How the military may be fueling eating disorders in men
    “Much of the rhetoric, imagery, and policy messaging from the Trump administration centers on extreme masculine ideals,” First Opinion author writes.
    STAT · 1mo ago↗ source
  • STAT+: NIH cuts weakened network primed to respond to outbreaks like Ebola
    While NIH-funded centers weren’t on the front lines of virus responses like the CDC or USAID, some researchers involved in the network said the cuts have damaged relationships with experts…
    STAT · 1mo ago↗ source
  • STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
    Advocates were already dreading Medicaid's work requirements. New rules are worse than they feared.
    STAT · 1mo ago↗ source
  • Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.
    A senior NIH scientist and his research fellow were charged with smuggling vials of deactivated mpox virus into the country from Africa and lying about it.
    STAT · 1mo ago↗ source
  • Lilly gives hospitals deadline to comply with 340B claims data policy
    Eli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push to…
    Endpoints · 1mo ago↗ source
  • FDA details flexibilities for new cell and gene therapies to leverage past data
    The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER…
    Endpoints · 1mo ago↗ source
  • Anti-aging biotech NewLimit raises $435M at $3B+ valuation
    The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said Tues…
    Endpoints · 1mo ago↗ source
  • STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
    Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
    STAT · 1mo ago↗ source
  • What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
    CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...
    Endpoints · 1mo ago↗ source